The "new" Ozempic tablets are basically the same as Rybelsus (they both use semaglutide as their main ingredient), just with a fresh label for better brand recognition in the US.
Novo Nordisk is also rolling out a subscription program that lowers monthly costs, hoping this combo helps them stand out in the crowded diabetes and obesity treatment market.